A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

被引：0
|
作者：
Jacqueline E. Paramarta
Maureen C. Turina
Troy Noordenbos
Tanja F. Heijda
Iris C. Blijdorp
Nataliya Yeremenko
Dominique Baeten
机构：
[1] Academic Medical Center/University of Amsterdam,Department of Clinical Immunology and Rheumatology
[2] Academic Medical Center/University of Amsterdam,Laboratory of Experimental Immunology
来源：
Journal of Translational Medicine | / 14卷
关键词：
Spondyloarthritis; Nilotinib; Tyrosine kinase inhibitor; Randomized controlled trial; Mast cells;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A proof-of-concept study of MEK inhibitor trametinib monotherapy in patients with biliary tract cancers
    Ioka, T.
    Ikeda, M.
    Fukutomi, A.
    Morizane, C.
    Kasuga, A.
    Takada, R.
    Takahashi, H.
    Todaka, A.
    Okusaka, T.
    Creasy, C.
    Gorman, S.
    Felitsky, D.
    Kawamura, T.
    Kobayashi, M.
    Furuse, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S464 - S464
  • [32] The Substrate-Activity-Screening methodology applied to receptor tyrosine kinases: A proof-of-concept study
    Chapelat, Julien
    Berst, Frederic
    Marzinzik, Andreas L.
    Moebitz, Henrik
    Drueckes, Peter
    Trappe, Joerg
    Fabbro, Doriano
    Seebach, Dieter
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2012, 57 : 1 - 9
  • [33] The paperless Labeling initiative: A proof-of-concept study
    Ruchalski, C
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (7-8) : 1178 - 1182
  • [34] Spesolimab for hidradenitis suppurativa: A proof-of-concept study
    Alavi, Afsaneh
    Prens, Errol
    Kimball, Alexa B.
    Krueger, James G.
    Mukhopadhyay, Sutirtha
    Wang, Hui
    Ivanoff, Nathalie B.
    Daly, Ana C. Hernandez
    Zouboulis, Christos C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB89 - AB89
  • [35] Proton Grid Therapy: A Proof-of-Concept Study
    Henry, Thomas
    Ureba, Ana
    Valdman, Alexander
    Siegbahn, Albert
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2017, 16 (06) : 749 - 757
  • [36] Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias
    Jabbour, Elias
    El Ahdab, Samih
    Cortes, Jorge
    Kantarjian, Hagop
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (07) : 1127 - 1136
  • [37] Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia
    Breccia, Massimo
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2010, 34 (02) : 129 - 134
  • [38] ATP-binding Cassette Transporter Inhibition by Tyrosine Kinase Inhibitor Nilotinib
    Quint, K.
    Di Fazio, P.
    Montalbano, R.
    Lingelbach, S.
    Ocker, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S248 - S248
  • [39] Leg ulcers occurring under tyrosine kinase inhibitor therapy (sunitinib, nilotinib)
    Roger, A.
    Sigal, M. -L.
    Bagan, P.
    Sin, C.
    Bilan, P.
    Dakhil, B.
    Fargeas, C.
    Couffinhal, J. -C.
    Mahe, E.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2017, 144 (01): : 49 - 54
  • [40] Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
    Alshiekh-Nasany, Ruham
    Zidan, Awss
    Martinez, Carmen
    CLINICAL CASE REPORTS, 2016, 4 (12): : 1184 - 1186
12345